Medicago is a biotechnology company focused on the discovery, development and commercialization of virus-like particles using plants as bioreactors to produce proteins as vaccine and drug candidates. The company was founded in 1997 in Quebec City, Canada in the United States.
As a pioneer in the field of transient expression and plant-based manufacturing, the company has always strived to find a more efficient way to improve humanity. The company’s technologies include production platforms and virus-like particles. The discovery platform encompasses vaccine discovery, antibody discovery and new indications such as cancer immunotherapy, which the company is looking forward to develop.
Medicago is engaged in the development of VLP-based vaccines that target various infectious diseases of viral or bacterial origin. The company’s primary products currently target common respiratory and enteric viruses.